Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 301–400 of 2,576
Yasojima, K., McGeer, E. G., & McGeer, P. L. (2001) · Brain Research · doi:10.1016/s0006-8993(01)03008-6 · Cited by 226
Bhatia, R., Lin, H., & Lal, R. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.9.1233 · Cited by 226
De Jonghe, C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.16.1665 · Cited by 223
Guo, Q., Christakos, S., Robinson, N., & Mattson, M. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3227 · Cited by 221
Combination assay of CSF Tau, Aβ1-40 and Aβ1-42(43) as a biochemical marker of Alzheimer's disease
Shoji, M., Matsubara, E., Kanai, M., Watanabe, M., Nakamura, T., Tomidokoro, Y., Shizuka, M., Wakabayashi, K., Igeta, Y., Ikeda, Y., et al. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00122-1 · Cited by 221
Nishimura, M., Yu, G., Levesque, G., Zhang, D. M., Ruel, L., Chen, F., Milman, P., Holmes, E., Liang, Y., Kawarai, T., et al. (1999) · Nature Medicine · doi:10.1038/5526 · Cited by 219
Self-citationThe Alzheimer family of diseases: Many etiologies, one pathogenesis?
Hardy, J. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2095 · Cited by 220
Self-citationLi, J., Xu, M., Zhou, H., Ma, J., & Potter, H. (1997) · Cell · doi:10.1016/s0092-8674(00)80356-6 · Cited by 172
“An indication that the presenilins may be involved in gene cell lines, and transgenic mice (Martins et al., 1995; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997). expression is provided by the finding that they function in the Notch signaling pathway in C. elegans (Levitan Consistent…”
Biomarkers of Alzheimer's disease
Craig-Schapiro, R., Fagan, A. M., & Holtzman, D. M. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.10.003 · Cited by 217
Zhang, C., McNeil, E., Dressler, L., & Siman, R. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.018 · Cited by 217
“When expressed in cellular systems, mice, and humans, the FAD-linked mutants invariably increase production of the Aβ42 variant (Scheuner et al., 1996;Hardy and Selkoe, 2002) that is the major component of parenchymal amyloid plaques (Yang et al., 1994;Savage et al., 1995).”
BackgroundMetabolism of amyloid-β peptide and Alzheimer's disease
Iwata, N., Higuchi, M., & Saido, T. C. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.03.010 · Cited by 220
The role of APP and BACE1 trafficking in APP processing and amyloid-β generation
Zhang, X., & Song, W. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt211 · Cited by 213
“mutant (KM/NL) APP produced significantly more Aβ (approximately threefold) than wild-type APP [32-35];”
BackgroundXia, W., Yang, T., Shankar, G., Smith, I. M., Shen, Y., Walsh, D. M., & Selkoe, D. J. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.565 · Cited by 216
“The use of C-terminal capturing antibodies and Nterminal or midregion detecting antibodies has been a standard format for measuring monomeric A species in many studies.(9,24-26) The capture antibodies 2G3 (to A residues 3340) and 21F12 (to A residues 33-42) were used for A 40 and A 42 species, respectively.”
InfluentialSelf-citationMetal Chelation as a Potential Therapy for Alzheimer's Disease
CUAJUNGCO, M. P., FAGÉT, K. Y., HUANG, X., TANZI, R. E., & BUSH, A. I. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06938.x · Cited by 215
Self-citationSiemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 216
Behavioral assays with mouse models of Alzheimer's disease: Practical considerations and guidelines
Puzzo, D., Lee, L., Palmeri, A., Calabrese, G., & Arancio, O. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.011 · Cited by 213
Keller, J. N., Guo, Q., Holtsberg, F. W., Bruce-Keller, A. J., & Mattson, M. P. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-12-04439.1998 · Cited by 215
Guerreiro, R. J., Baquero, M., Blesa, R., Boada, M., Brás, J. M., Bullido, M. J., Calado, A., Crook, R., Ferreira, C., Frank, A., et al. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.06.012 · Cited by 216
“It produces a greater proportion of Aβ42 (Scheuner et al., 1996; Qi et al., 2003; Qi-Takahara et al., 2005) and fits the helix rule (Hardy and Crook, 2001), aligning with other mutations in transmembrane domain 5 (Figure 1).”
BackgroundInfluentialSelf-citationIn vivo detection of amyloid plaques in a mouse model of Alzheimer's disease
Skovronsky, D. M., Zhang, B., Kung, M.-P., Kung, H. F., Trojanowski, J. Q., & Lee, V. M.-Y. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7609 · Cited by 214
The LEARn model: an epigenetic explanation for idiopathic neurobiological diseases
Lahiri, D. K., Maloney, B., & Zawia, N. H. (2009) · Molecular Psychiatry · doi:10.1038/mp.2009.82 · Cited by 211
Weidemann, A., Paliga, K., Dürrwang, U., Czech, C., Evin, G., Masters, C. L., & Beyreuther, K. (1997) · Nature Medicine · doi:10.1038/nm0397-328 · Cited by 214
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Amyloid-β causes memory impairment by disturbing the JAK2/STAT3 axis in hippocampal neurons
Chiba, T., Yamada, M., Sasabe, J., Terashita, K., Shimoda, M., Matsuoka, M., & Aiso, S. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.105 · Cited by 194
Lee, S.-F., Shah, S., Li, H., Yu, C., Han, W., & Yu, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208164200 · Cited by 211
Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies
Selkoe, D. J. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-8-200404200-00047 · Cited by 208
Self-citationMolecular genetics of Alzheimer's disease: An update
Brouwers, N., Sleegers, K., & Van Broeckhoven, C. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 208
Endoproteolytic Cleavage and Proteasomal Degradation of Presenilin 2 in Transfected Cells
Kim, T.-W., Pettingell, W. H., Hallmark, O. G., Moir, R. D., Wasco, W., & Tanzi, R. E. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.17.11006 · Cited by 210
Self-citationIntramembrane Proteolysis by γ-Secretase
Steiner, H., Fluhrer, R., & Haass, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800010200 · Cited by 206
Levites, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25410 · Cited by 207
Passer, B., Pellegrini, L., Russo, C., Siegel, R. M., Lenardo, M. J., Schettini, G., Bachmann, M., Tabaton, M., & D'Adamio, L. (2000) · Journal of Alzheimer's Disease · doi:10.3233/jad-2000-23-408 · Cited by 207
The Toxicity of the Alzheimer's β-Amyloid Peptide Correlates with a Distinct Fiber Morphology
Seilheimer, B., Bohrmann, B., Bondolfi, L., Müller, F., Stüber, D., & Döbeli, H. (1997) · Journal of Structural Biology · doi:10.1006/jsbi.1997.3859 · Cited by 210
The Alzheimer's disease mitochondrial cascade hypothesis: an update
Swerdlow, R. H., & Khan, S. M. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.01.011 · Cited by 206
“…hypothesis was subsequently bolstered by work showing presenilin (PS) 1 and 2 mutations also cause AD, and that APP, PS1, and PS2 mutation all favor processing of APP to its 42 amino acid beta amyloid (Aβ) derivative (Levy-Lahad et al., 1995; Sherrington et al., 1995; Scheuner et al., 1996).”
BackgroundAlzheimer’s Disease And Inflammation: A Review Of Cellular And Therapeutic Mechanisms
Halliday, G., Robinson, S. R., Shepherd, C., & Kril, J. (2000) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2000.03200.x · Cited by 208
Full genome screen for Alzheimer disease: Stage II analysis*
Myers, A., Wavrant De‐Vrieze, F., Holmans, P., Hamshere, M., Crook, R., Compton, D., Marshall, H., Meyer, D., Shears, S., Booth, J., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10183 · Cited by 207
Self-citationCholesterol, a modulator of membrane-associated aβ-fibrillogenesis and neurotoxicity
Yip, C. M., Elton, E. A., Darabie, A. A., Morrison, M. R., & McLaurin, J. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4881 · Cited by 207
Molecular Mechanisms and Genetics of Oxidative Stress in Alzheimer’s Disease
Cioffi, F., Adam, R. H. I., & Broersen, K. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190863 · Cited by 204
Molecular biology and genetics of Alzheimer's disease
St George-Hyslop, P. H., & Petit, A. (2005) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2004.10.013 · Cited by 210
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2012) · Advances in Experimental Medicine and Biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 198
“It is caused by mutations in genes encoding for either the amyloid precursor protein (APP), presenilin 1 (PS1), or presenilin (PS2), and these mutations appear to alter processing of APP towards the 42 amino acid beta amyloid (Aβ) derivative (Scheuner et al., 1996).”
BackgroundBrain-Derived Neurotrophic Factor and Alzheimer’s Disease: Physiopathology and Beyond
Diniz, B. S., & Teixeira, A. L. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-011-8154-x · Cited by 201
Ramakrishna, K., Nalla, L. V., Naresh, D., Venkateswarlu, K., Viswanadh, M. K., Nalluri, B. N., Chakravarthy, G., Duguluri, S., Singh, P., Rai, S. N., et al. (2023) · Diseases · doi:10.3390/diseases11030089 · Cited by 192
Harigaya, Y., Saido, T. C., Eckman, C. B., Prada, C.-M., Shoji, M., & Younkin, S. G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3490 · Cited by 202
Self-citationBorg, J.-P., Yang, Y., De Taddéo-Borg, M., Margolis, B., & Turner, R. S. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.14761 · Cited by 201
Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease
Gallardo, G., & Holtzman, D. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-32-9358-8_16 · Cited by 198
Redwine, J. M., Kosofsky, B., Jacobs, R. E., Games, D., Reilly, J. F., Morrison, J. H., Young, W. G., & Bloom, F. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242746599 · Cited by 202
Smith, M. A. (1998) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60607-8 · Cited by 194
Curtain, C. C., Ali, F. E., Smith, D. G., Bush, A. I., Masters, C. L., & Barnham, K. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205455200 · Cited by 200
Maloney, J. A., Bainbridge, T., Gustafson, A., Zhang, S., Kyauk, R., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589069 · Cited by 197
Emerging roles of pathogens in Alzheimer disease
Miklossy, J. (2011) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399411002006 · Cited by 201
Membrane Topology of the C. elegans SEL-12 Presenilin
Li, X., & Greenwald, I. (1996) · Neuron · doi:10.1016/s0896-6273(00)80231-7 · Cited by 202
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman, J. M., Younkin, S. G., Pratico, D., Seltzer, W., Cole, G. M., Geschwind, D. H., Rodriguez-Agudelo, Y., Schaffer, B., Fein, J., Sokolow, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000303973.71803.81 · Cited by 198
Self-citationParks, J. K., Smith, T. S., Trimmer, P. A., Bennett, J. P., & Parker, W. D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00112.x · Cited by 199
Guo, Q., Sebastian, L., Sopher, B. L., Miller, M. W., Ware, C. B., Martin, G. M., & Mattson, M. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721019.x · Cited by 197
“Studies of transfected cell lines and tissues from AD patients and transgenic mice suggest a role for increased production of an amyloidogenic form of Ab (Ab1–42) in the pathogenic mechanism of PS1 mutations (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996).”
BackgroundMeftah, S., & Gan, J. (2023) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2023.1129036 · Cited by 205
“These mutations lead to enhanced production or accumulation of Aβ, or increase the ratio between Aβ42 to Aβ40 within the brain (St George-Hyslop et al., 1987; Goate et al., 1991; Scheuner et al., 1996; Bekris et al., 2010).”
BackgroundGuo, Q., Robinson, N., & Mattson, M. P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.20.12341 · Cited by 196
Wong, T. P., Debeir, T., Duff, K., & Cuello, A. C. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02706.1999 · Cited by 196
“Mutations in PS1 (such as PS1M146L ) all lead to the elevation of Ab1–42(43) only, by an unknown mechanism (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997).”
BackgroundSmall heat-shock proteins: important players in regulating cellular proteostasis
Treweek, T. M., Meehan, S., Ecroyd, H., & Carver, J. A. (2015) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1754-5 · Cited by 194
“overproduction of A leads to early onset AD [194-197].”
BackgroundEckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196
Self-citationAmyloid β Protein-(1–42) Forms Calcium-permeable, Zn2+-sensitive Channel
Rhee, S. K., Quist, A. P., & Lal, R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.22.13379 · Cited by 195
Steiner, H., Capell, A., Pesold, B., Citron, M., Kloetzel, P. M., Selkoe, D. J., Romig, H., Mendla, K., & Haass, C. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.48.32322 · Cited by 195
Self-citationSkoog, I., Davidsson, P., Aevarsson, Ó., Vanderstichele, H., Vanmechelen, E., & Blennow, K. (2003) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000068478 · Cited by 194
Molecular Dynamics Simulation of Amyloid β Dimer Formation
Urbanc, B., Cruz, L., Ding, F., Sammond, D., Khare, S., Buldyrev, S. V., Stanley, H. E., & Dokholyan, N. V. (2004) · Biophysical Journal · doi:10.1529/biophysj.104.040980 · Cited by 194
“…they display distinct behavior, with Aβ(1–42) being a predominant component of parenchymal plaques (Suzuki et al., 1994; Iwatsubo et al., 1994; Gravina et al., 1995), associated with both early onset AD (Scheuner et al., 1996; Golde et al., 2000) and increased risk for AD (Weggen et al., 2001).”
Weggen, S., & Beher, D. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt107 · Cited by 192
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 190
PSEN1ΔE9, APPswe, and APOE4 Confer Disparate Phenotypes in Human iPSC-Derived Microglia
Konttinen, H., Cabral-da-Silva, M. E. C., Ohtonen, S., Wojciechowski, S., Shakirzyanova, A., Caligola, S., Giugno, R., Ishchenko, Y., Hernández, D., Fazaludeen, M. F., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.08.004 · Cited by 191
“…in amounts of Ab, suggesting that Ab burden associated with PSEN1DE9, APPswe, and APOE4 is of neuronal and astrocytic origin (Oberstein et al., 2015; Scheuner et al., 1996), and that human microglia with these genotypes harbor alternative mechanisms underlying development and progression of AD.”
BackgroundWolfe, M. S. (2007) · EMBO reports · doi:10.1038/sj.embor.7400896 · Cited by 192
Wen, P. H., Hof, P. R., Chen, X., Gluck, K., Austin, G., Younkin, S. G., Younkin, L. H., DeGasperi, R., Gama Sosa, M. A., Robakis, N. K., et al. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.04.002 · Cited by 189
Self-citationAlzheimer's Disease: Redox Dysregulation As a Common Denominator for Diverse Pathogenic Mechanisms
von Bernhardi, R., & Eugenín, J. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4082 · Cited by 190
APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1
Jankowsky, J. L., Slunt, H. H., Gonzales, V., Jenkins, N. A., Copeland, N. G., & Borchelt, D. R. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.008 · Cited by 191
Calcium Dyshomeostasis in Alzheimer’s Disease Pathogenesis
Cascella, R., & Cecchi, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094914 · Cited by 185
Therapeutic strategies for Alzheimer's disease
Wolfe, M. S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd938 · Cited by 190
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 188
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188
Theuns, J., Brouwers, N., Engelborghs, S., Sleegers, K., Bogaerts, V., Corsmit, E., De Pooter, T., van Duijn, C. M., De Deyn, P. P., & Van Broeckhoven, C. (2006) · The American Journal of Human Genetics · doi:10.1086/504044 · Cited by 188
Zou, K., Yamaguchi, H., Akatsu, H., Sakamoto, T., Ko, M., Mizoguchi, K., Gong, J.-S., Yu, W., Yamamoto, T., Kosaka, K., et al. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.1549-07.2007 · Cited by 187
β‐Amyloid Degradation and Alzheimer′s Disease
Wang, D.-S., Dickson, D. W., & Malter, J. S. (2006) · BioMed Research International · doi:10.1155/jbb/2006/58406 · Cited by 185
Using Knockout and Transgenic Mice to Study Neurophysiology and Behavior
PICCIOTTO, M. R., & WICKMAN, K. (1998) · Physiological Reviews · doi:10.1152/physrev.1998.78.4.1131 · Cited by 186
Biology of Aβ Amyloid in Alzheimer's Disease
Wisniewski, T., Ghiso, J., & Frangione, B. (1997) · Neurobiology of Disease · doi:10.1006/nbdi.1997.0147 · Cited by 134
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 182
Platelet Activation in Alzheimer Disease
Sevush, S., Jy, W., Horstman, L. L., Mao, W.-W., Kolodny, L., & Ahn, Y. S. (1998) · Archives of Neurology · doi:10.1001/archneur.55.4.530 · Cited by 185
Advances in the Cellular and Molecular Biology of the Beta-Amyloid Protein in Alzheimer 's Disease
Sambamurti, K., Greig, N. H., & Lahiri, D. K. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:1:1:1 · Cited by 185
Coffey, E. E., Beckel, J. M., Laties, A. M., & Mitchell, C. H. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.001 · Cited by 189
“While the protein with this point mutation is still capable cleaving amyloid precursor protein, it is associated both with elevated Aı42/40 ratio (Scheuner et al., 1996, Qian et al., 1998) and autophagic pathology (Lee et al., 2010).”
Annaert, W. G., Esselens, C., Baert, V., Boeve, C., Snellings, G., Cupers, P., Craessaerts, K., & De Strooper, B. (2001) · Neuron · doi:10.1016/s0896-6273(01)00512-8 · Cited by 184
Mann, D. M. A., Pickering-Brown, S. M., Takeuchi, A., & Iwatsubo, T. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64688-3 · Cited by 182
Hedden, T., Mormino, E. C., Amariglio, R. E., Younger, A. P., Schultz, A. P., Becker, J. A., Buckner, R. L., Johnson, K. A., Sperling, R. A., & Rentz, D. M. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2462-12.2012 · Cited by 182
“The impact of amyloid burden on cognition among cognitively normal individuals has become a topic of immense interest since the advent of in vivo amyloid imaging and the ability to measure CSF biomarkers of amyloid (Klunk et al., 2004; Scheuner et al., 1996).”
BackgroundA Cell Biological Perspective on Alzheimer's Disease
Annaert, W., & De Strooper, B. (2002) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.18.020402.142302 · Cited by 182
Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease
PAKASKI, M., & KALMAN, J. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.06.005 · Cited by 178
Can oral infection be a risk factor for Alzheimer's disease?
Olsen, I., & Singhrao, S. K. (2015) · Journal of Oral Microbiology · doi:10.3402/jom.v7.29143 · Cited by 180
High Levels of Circulating Aβ42 Are Sequestered by Plasma Proteins in Alzheimer's Disease
Kuo, Y.-M., Emmerling, M. R., Lampert, H. C., Hempelman, S. R., Kokjohn, T. A., Woods, A. S., Cotter, R. J., & Roher, A. E. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0552 · Cited by 182
Presenilin 1 Is Required for Maturation and Cell Surface Accumulation of Nicastrin
Leem, J. Y., Vijayan, S., Han, P., Cai, D., Machura, M., Lopes, K. O., Veselits, M. L., Xu, H., & Thinakaran, G. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.c200148200 · Cited by 181
Leissring, M. A., Paul, B. A., Parker, I., Cotman, C. W., & LaFerla, F. M. (1999) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1999.721061.x · Cited by 162
A β 42 and A β 40: similarities and differences
Qiu, T., Liu, Q., Chen, Y., Zhao, Y., & Li, Y. (2015) · Journal of Peptide Science · doi:10.1002/psc.2789 · Cited by 180
McGowan, E., Sanders, S., Iwatsubo, T., Takeuchi, A., Saido, T., Zehr, C., Yu, X., Uljon, S., Wang, R., Mann, D., et al. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0243 · Cited by 185
“…a higher burden, or number, of Ab42 senile plaques compared with patients with sporadic AD (Mann et al., 1996), most likely due to the effect of mutant PS1 on APP metabolism which leads to specific elevation of the highly fibrillogenic Ab42 peptide (Scheuner et al., 1996; Jarrett et al., 1993).”
BackgroundThe Genetics of Alzheimer Disease: Current Status and Future Prospects
Blacker, D., & Tanzi, R. E. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.294 · Cited by 182
Self-citationSproul, A. A., Jacob, S., Pre, D., Kim, S. H., Nestor, M. W., Navarro-Sobrino, M., Santa-Maria, I., Zimmer, M., Aubry, S., Steele, J. W., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084547 · Cited by 162
“Fibroblasts from PSEN1 mutant patients have been observed to produce an increased ratio of Ab42/Ab40, thus enhancing the relative levels of the more oligomerogenic Ab peptide [28,29].”
BackgroundSpoelgen, R., von Arnim, C. A. F., Thomas, A. V., Peltan, I. D., Koker, M., Deng, A., Irizarry, M. C., Andersen, O. M., Willnow, T. E., & Hyman, B. T. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.3882-05.2006 · Cited by 148
“The sensitivity of this ELISA assay is 1 pM A , and it is not affected by serum and plasma proteins because of the high affinity of the antibodies (Scheuner et al., 1996; Kosaka et al., 1997; Fukumoto et al., 2003).”
BackgroundThe Chaperone BiP/GRP78 Binds to Amyloid Precursor Protein and Decreases Aβ40 and Aβ42 Secretion
Yang, Y., Turner, R. S., & Gaut, J. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25552 · Cited by 178
Woodruff, G., Young, J. E., Martinez, F. J., Buen, F., Gore, A., Kinaga, J., Li, Z., Yuan, S. H., Zhang, K., & Goldstein, L. S. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.018 · Cited by 177
VERDILE, G. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.028 · Cited by 169
“Conditioned media from fibroblasts or plasma from affected pedigrees with PS1 and PS2 mutations have been reported to have an increased ratio of A 42/40, relative to unaffected family members [49].”
BackgroundMicroglia as a Potential Bridge between the Amyloid β‐Peptide and Tau
KITAZAWA, M., YAMASAKI, T. R., & LAFERLA, F. M. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.006 · Cited by 176
Multifunctional roles of enolase in Alzheimer’s disease brain: beyond altered glucose metabolism
Butterfield, D. A., & Lange, M. L. B. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06397.x · Cited by 177
“However, in rare instances it can affect younger populations, as early as 30 years old, in FAD (Citron et al. 1992; Scheuner et al. 1996; Sturchler-Pierrat et al. 1997; Wisniewski et al. 1998).”
Background
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.